PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met

EQS-News: PharmaSGP Holding SE / Key word(s): Squeeze Out/Share Buyback PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met 18.06.2025 / 17:29 CET/CEST The issuer is solely responsible for the content of this announcement. PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met

Gräfelfing, June 18, 2025 – PharmaSGP SE (ISIN: DE000A2P4LJ5) currently holds treasury shares representing approximately 4.06% of its share capital as a result of last year's share buyback. In order to make optimal use of the new authorization to acquire treasury shares proposed for resolution at the upcoming Annual General Meeting, the company intends to retire these treasury shares in the short term. Against the backdrop of the upcoming delisting, there is currently no need for any other use of the treasury shares.

The redemption reduces the company's share capital accordingly. However, the redemption of treasury shares has no effect on the existing economic interest of the shareholders, as treasury shares do not carry any rights. The reduction of the share capital merely increases the shareholders’ percentage ownership on an arithmetical basis. As a result, the share of the company's two main shareholders, FUTRUE GmbH and MVH Beteiligungs- und Beratungs-GmbH, in the share capital will arithmetically increase to a total of approximately 94%. They thus jointly hold a stake which, even without a further increase in shares, allows for the implementation of a so-called squeeze-out under conversion law (Section 62 para. 5 of the German Transformation Act (Umwandlungsgesetz) in conjunction with Section 327a of the German Stock Corporation Act (Aktiengesetz)).

 

CONTACT

cometis AG
Jakob Hafer
Phone: [phone]
Email: [e-mail]

 

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.